Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
212 stopped studies mapped to Soft Tissue Sarcoma and descendants · 92% state a reason
Over the 212 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05264974 | Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization | Phase 1 | suspended | Mar 3, 2022 | University of Florida | seeking additional funding | Funding |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic… | Phase 1 | suspended | May 13, 2025 | Washington University School of Medicine | Protocol amendment | Other (stated, no rule matched) |
| NCT05813327 | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | Phase 1 | terminated | Apr 14, 2023 | Washington University School of Medicine | Polaris decided to close to accrual. | Enrollment / accrual |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT05109494 | Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas | Phase 2 | suspended | Nov 5, 2021 | University of Wisconsin, Madison | Administrative | Other (stated, no rule matched) |
| NCT04037527 | Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the… | Phase 1 | terminated | Jul 30, 2019 | Wake Forest University Health Sciences | Terminated due DLTs | Other (stated, no rule matched) |
| NCT05712694 | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With… | Phase 3 | terminated | Feb 3, 2023 | Polaris Group | Lack of Efficacy, no safety concern. | Safety / toxicity |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients… | Phase 3 | terminated | Nov 13, 2009 | National Cancer Institute (NCI) | The study was targeted to accrue 130 patients, but closed early for futility. | Efficacy / futility |
| NCT07136571 | Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable… | N/A | withdrawn | Aug 22, 2025 | University of Alabama at Birmingham | Study PI is leaving UAB and no longer opening study. | Other (stated, no rule matched) |
| NCT05549921 | Phase II Study of TAEST16001 in Soft Tissue Sarcoma | Phase 2 | terminated | Sep 22, 2022 | Sun Yat-sen University | The study was terminated due to initiation of a new clinical trial with an updated study design. | Other (stated, no rule matched) |
| NCT01412515 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral… | Phase 2 | terminated | Aug 9, 2011 | Institut National de la Santé Et de la Recherche Médicale, France | results from interim analysis conducted to study interruption | Efficacy / futility |
| NCT04123535 | Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma(HIFU-UPS) | N/A | terminated | Oct 11, 2019 | Matthew Bucknor | Slow accrual | Enrollment / accrual |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT01612481 | Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High…(CASSANDRE) | Phase 2 | terminated | Jun 5, 2012 | Centre Oscar Lambret | lack of enrollment | Enrollment / accrual |
| NCT05116254 | Sarcomas and DDR-Inhibition; a Combined Modality Study(SADDRIN-1) | Phase 1 | terminated | Nov 10, 2021 | The Netherlands Cancer Institute | Endpoint has been reached. | Other (stated, no rule matched) |
| NCT05846724 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) | Phase 2 | withdrawn | May 6, 2023 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | The lack of adequate funding has made it impossible to continue with the clinical study As this… | Funding |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory… | Phase 1 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05481645 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib… | Phase 2 | terminated | Aug 1, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT04204941 | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced… | Phase 1 | terminated | Dec 19, 2019 | Epizyme, Inc. | FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required… | Safety / toxicity |
| NCT06050434 | Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With…(PROTraSarc) | — | terminated | Sep 22, 2023 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | The study was terminated prematurely due to slow recruitment after inclusion of 7 patients (of… | Enrollment / accrual |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT06058728 | A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules…(Pink Orchid) | — | withdrawn | Sep 28, 2023 | AbbVie | Company Decision | Sponsor / business decision |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT06670976 | Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients… | Phase 1 | withdrawn | Nov 1, 2024 | Roswell Park Cancer Institute | to be submitted at a later date | Other (stated, no rule matched) |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | terminated | May 27, 2016 | Eli Lilly and Company | The study was terminated due to business considerations | Sponsor / business decision |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural… | Phase 2 | terminated | Aug 23, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | Phase 3 | terminated | Jun 21, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT04220229 | Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | Phase 1 / Phase 2 | terminated | Jan 7, 2020 | University of Washington | Terminated due to end of funding | Funding |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or… | Phase 2 | terminated | Aug 28, 2020 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT04148378 | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | — | withdrawn | Nov 1, 2019 | ProgenaBiome | Company shifted focus | Sponsor / business decision |
| NCT04347122 | Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction | Phase 4 | terminated | Apr 15, 2020 | University of Kansas Medical Center | recruitment stalled | Enrollment / accrual |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | Phase 2 | withdrawn | May 18, 2010 | Situs Cancer Research Center | Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche… | Drug supply |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT03660930 | Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced… | Phase 1 / Phase 2 | terminated | Sep 7, 2018 | University of Washington | Study was terminated at completion of the Phase 1 dose escalation due to loss of financial support. | Funding |
| NCT06106633 | Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization(PEDD-UFE) | N/A | terminated | Oct 30, 2023 | Massachusetts General Hospital | Insufficient Enrollment | Enrollment / accrual |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With… | Phase 1 | terminated | Dec 22, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04965753 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Phase 1 | terminated | Jul 16, 2021 | Foghorn Therapeutics Inc. | Sponsor decision | Sponsor / business decision |
| NCT06494787 | A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma(SOC-2320) | Phase 2 | withdrawn | Jul 10, 2024 | Sarcoma Oncology Research Center, LLC | Lack of funding | Funding |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT05100628 | A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue… | Phase 1 | terminated | Oct 29, 2021 | Noxopharm Limited | Slow recruitment | Enrollment / accrual |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | Phase 2 | withdrawn | Mar 10, 2021 | Children's National Research Institute | Low enrollment. | Enrollment / accrual |
| NCT05355753 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or… | Phase 1 | terminated | May 2, 2022 | C4 Therapeutics, Inc. | High levels of BRD9 degradation did not result in sufficient efficacy in heavily pre-treated… | Efficacy / futility |
| NCT03118037 | Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry(SAGE) | — | terminated | Apr 18, 2017 | Gynesonics | Termination due to continued lack of patient compliance | Other (stated, no rule matched) |
| NCT05017103 | Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable… | Phase 2 | terminated | Aug 23, 2021 | M.D. Anderson Cancer Center | The drug sponsor stopped supporting study. | Other (stated, no rule matched) |
| NCT06217536 | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | Phase 1 / Phase 2 | withdrawn | Jan 22, 2024 | University of California, San Francisco | Business decision | Sponsor / business decision |
| NCT03116529 | Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma(NEXIS) | Phase 1 / Phase 2 | terminated | Apr 17, 2017 | University of Maryland, Baltimore | Limited Accrual | Enrollment / accrual |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid…(CAR) | Phase 1 | terminated | May 22, 2019 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials